SCHEMBL3053166

SCHEMBL3053166

COC(=O)c1ccc(C=C(C(=O)NCc2ccc(C(=O)Nc3ccccc3N)cc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
MAPT P10636 1/20 0.62
HDAC1 Q13547 5/20 0.61
HDAC3 O15379 2/20 0.58
HDAC2 Q92769 2/20 0.58
HDAC4 P56524 1/20 0.58
HDAC7 Q8WUI4 1/20 0.58
HDAC10 Q969S8 1/20 0.58
HDAC11 Q96DB2 1/20 0.58
HDAC8 Q9BY41 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
HDAC9 Q9UKV0 1/20 0.58
HDAC5 Q9UQL6 1/20 0.58
NCOR1 O75376 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8081889 1.00 LMNA (0.62) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL3043797 0.94 LMNA (0.70) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL8071235 0.94 LMNA (0.70) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL13177815 0.94 LMNA (0.57) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL3052251 0.92 LMNA (0.61) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL8076326 0.92 LMNA (0.61) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL8081199 0.92 LMNA (0.61) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL3056716 0.92 LMNA (0.61) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL3049010 0.90 HDAC1 (0.59) LMNAMAPTHDAC1HDAC3HDAC2
SCHEMBL13136781 0.90 HDAC1 (0.59) LMNAMAPTHDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476255-B2 Histone deacetylase inhibitors ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2013-07-02 US claimed
US-20100222379-A1 NOVEL HISTONE DEACETYLASE INHIBITORS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2010-09-02 US claimed
EP-2205563-A2 NOVEL HISTONE DEACETYLASE INHIBITORS Orchid Research Laboratories Limited (IN) 2010-07-14 EP claimed
WO-2009047615-A2 NOVEL HISTONE DEACETYLASE INHIBITORS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2009-04-16 WO claimed
US-8476255-B2 Histone deacetylase inhibitors ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2013-07-02 US disclosed
US-20100222379-A1 NOVEL HISTONE DEACETYLASE INHIBITORS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2010-09-02 US disclosed
EP-2205563-A2 NOVEL HISTONE DEACETYLASE INHIBITORS Orchid Research Laboratories Limited (IN) 2010-07-14 EP disclosed
WO-2009047615-A2 NOVEL HISTONE DEACETYLASE INHIBITORS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222379-A1 NOVEL HISTONE DEACETYLASE INHIBITORS HDAC5, HDAC2, HDAC1 LMNA 2522/4885MAPT 342/4885HDAC1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.